Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Am J Hematol. 2023 Jul;98(7):E183-E186. doi: 10.1002/ajh.26943. Epub 2023 May 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dasatinib
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Leukemia, Myeloid, Chronic-Phase*
  • Protein Kinase Inhibitors / pharmacology
  • Protein-Tyrosine Kinases

Substances

  • Imatinib Mesylate
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Dasatinib